DEA publishes guidance on new training requirements for prescribers of controlled substances On March 28, 2023, the U.S. Substance Abuse and Mental Health Services Administration (SAMHSA) released recommendations and the U.S. Drug Enforcement Administration (DEA) issued specific guidance on how practitioners can meet the new training requirements for DEA-registered prescribers of controlled substances. The new law requires all prescribers of schedule II – V controlled substances to meet a one-time eight-hour training requirement on identifying, treating, and managing patients with opioid or other substance use disorders. Many California-licensed physicians may have already met the new DEA requirements because California requires similar education. While the California Medical Association (CMA) did not ... April 6, 2023 DEA, Drug Prescribing/Dispensing, General, Healthcare, Mental Health, Patient Care SAMHSA, TRAINING 0 0 Comment Read More »
SCC HEALTH ADVISORY: Xylazine Presence in Illicit Drug Supply (P2) DATE: April 3, 2023 TO: All Healthcare Providers FROM: Michelle Jorden, MD, F-ABMDI Chief Medical Examiner - Coroner Akanksha Vaidya, MD, MPH Assistant Public Health Officer HEALTH ADVISORY: XYLAZINE PRESENCE IN ILLICIT DRUG SUPPLY Xylazine, a non-opioid agent developed as a veterinary tranquilizer, has been increasingly detected in the nation’s illicit opioid supply. Xylazine has been associated with fatal overdoses and chronic wounds, with areas in the Northeast USA being heavily impacted. The U.S. Drug Enforcement Administration (DEA) Laboratory System reported that in 2022, approximately 23% of fentanyl powder and 7% of fentanyl pills seized by the DEA contained xylazine. In Santa ... April 3, 2023 General, Healthcare, Public Health 0 0 Comment Read More »
